37 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation
SC TO-T/A
EX-99
RYZB
RayzeBio Inc.
23 Feb 24
Third party tender offer statement (amended)
7:34am
to the consummation of the proposed transaction and/or potential difficulties in employee retention as a result of the consummation of the proposed transaction
424B5
BMY
Bristol-Myers Squibb Co.
16 Feb 24
Prospectus supplement for primary offering
4:34pm
response of business partners and competitors and/or potential difficulties in employee retention as a result of the Acquisitions.
The foregoing list sets
424B2
BMY
Bristol-Myers Squibb Co.
13 Feb 24
Prospectus for primary offering
8:00am
in employee retention as a result of the Acquisitions.
The foregoing list sets forth some, but not all, of the factors that could have an impact upon our
SC TO-T/A
EX-99
RYZB
RayzeBio Inc.
12 Feb 24
Third party tender offer statement (amended)
7:34am
of the proposed transaction and/or potential difficulties in employee retention as a result of the consummation of the proposed transaction. Forward
SC TO-C
EX-99.3
10y3t737n7o120um
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
81r1qm
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.2
q3y sw91htkkqx
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.5
arqa 2j4uc
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.1
ihrs5
26 Dec 23
Information about tender offer
4:22pm
SC TO-C
EX-99.4
1ogbm
26 Dec 23
Information about tender offer
4:22pm
DFAN14A
fj8pq8oploo04egks
22 Dec 23
Additional proxy materials by non-management
4:36pm
DFAN14A
EX-99.1
feb5zl4v386kd8s l2
22 Dec 23
Additional proxy materials by non-management
4:21pm
DFAN14A
8u5dglkmm03
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
en4wri3 yp3wnlx5
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
8-K
j7mzr 9yqmlh1
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
424B5
aiznz
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
6dxcvyq5
30 Oct 23
Prospectus supplement
8:05am
DFAN14A
hcji2t1o5 g2
10 Oct 23
Additional proxy materials by non-management
6:48am
SC TO-T/A
EX-99.1
0rnqdjaocat
16 Aug 22
Third party tender offer statement (amended)
7:08am